Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-γ agonists induced apoptosis in human monocyte leukemia cells in vitro

Annals of Hematology

Volumn 86, Issue 3, 2007, Pages 173-183

  Liu, Jia Jun ^a   Liu, Pei Qing ^a   Lin, Dong Jun ^a   Xiao, Ruo Zhi ^a   Huang, Min ^a   Li, Xu Dong ^a   He, Yi ^a   Huang, Ren Wei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bcl 2; Cyclooxygenase 2 (COX 2); Human monocyte leukemia cell; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CASPASE 3; CYCLOOXYGENASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; LIPID METABOLISM; MEMBRANE POTENTIAL; MITOCHONDRION; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CHROMANS; CYCLOOXYGENASE 2; DNA, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MONOCYTES; PPAR GAMMA; PROSTAGLANDIN D2; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES; THYMIDINE; U937 CELLS;

EID: 33846651029     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0205-2     Document Type: Article

References (46)

1. Jabbour EJ, Estey E, Kantarjian HM (2006) Adult acute myeloid leukemia. Mayo Clin Proc 81:247-260
2. Macheta M, Yin JA (2001) Recent advances in the treatment of AML. Hematol Oncol 19:107-118
3. Glass CK, Ogawa S (2006) Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6:44-55
4. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120-159
5. Lehrke M, Lazar MA (2006) The many faces of PPAR gamma. Cell 123:993-999
6. Gurnell M (2005) Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: Lessons from human genetic studies. Best Pract Res Clin Endocrinol Metab 19:501-523
7. Nemenoff RA, Winn RA (2005) Role of nuclear receptors in lung tumourigenesis. Eur J Cancer 41:2561-2568
8. Kawamata H, Tachibana M, Fujimori T, Imai Y (2006) Differentiation-inducing therapy for solid tumors. Curr Pharm Des 12:379-385
9. Panigrahy D, Huang S, Kieran MW, Kaipainen A (2005) PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 4:687-693
10. Coyle AT, O'Keeffe MB, Kinsella BT (2005) 15-deoxy Delta12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells. FEBS J 272:4754-4773
11. Coyle AT, Kinsella BT (2006) Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. Biochem Pharmacol 71:1308-1323
12. Liu H, Zang C, Fenner MH, Liu D, Possinger K, Koeffler HP, Elstner E (2006) Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 107:3683-3692
13. Smith WL, Langenbach R (2001) Why there are two cyclooxygenase isozymes. J Clin Invest 107:1491-1495
14. Morita I (2002) Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68-69:165-175
15. Lu S, Yu G, Zhu Y, Archer MC (2005) Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation. Int J Cancer 116:847-852
16. Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy. Semin Oncol 31(2S7):2-11
17. Gately S (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19:19-27
18. Secchiero P, Barbarotto E, Gonelli A, Tiribelli M, Zerbinati C, Celeghini C, Agostinelli C, Pileri SA, Zauli G (2005) Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells. Am J Pathol 167:1599-1607
19. Subhashini J, Mahipal SV, Reddanna P (2005) Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224:31-43
20. Chao SH, Wu AB, Lee CJ, Chen FA, Wang CC (2005) Anti-inflammatory effects of indomethacin's methyl ester derivative and induction of apoptosis in HL-60 cells. Biol Pharm Bull 28:2206-2210
21. Hull MA (2005) Cyclooxygenase-2: How good is it as a target for cancer chemoprevention? Eur J Cancer 41:1854-1863
22. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP (2004) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23:1000-1009
23. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M (2004) PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 18:528-540
24. Pham H, Banerjee T, Nalbandian GM, Ziboh VA (2003) Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by 15S-hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett 189:17-25
25. Panigrahy D, Shen LQ, Kieran MW, Kaipainen A (2003) Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12:1925-1932
26. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE (2006) Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer118:773-779
27. Theocharis S, Margeli A, Vielh P, Kouraklis G (2004) Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 30:545-551
28. Chen YC, Shen SC, Tsai SH (2005) Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim Biophys Acta 1743:291-304
29. Wang T, Xu J, Yu X, Yang R, Han ZC (2006) Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 58:1-14
30. Dempke W, Rie C, Grothey A, Schmoll HJ (2001) Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127:411-417
31. Gately S, Kerbel R (2003) Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37:179-192
32. Oshima M, Taketo MM (2002) COX selectivity and animal models for colon cancer. Curr Pharm Des 8:1021-1034
33. Park C, Choi BT, Kang KI, Kwon TK, Cheong J, Lee WH, Kim ND, Choi YH (2005) Induction of apoptosis and inhibition of cyclooxygenase-2 expression by N-methyl-N-nitro-N-nitrosoguanidine in human leukemia cells. Anticancer Drugs 16:507-513
34. Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF (2004) Imrecoxib: A novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin 25:927-931
35. Danz H, Stoyanova S, Thomet OA, Simon HU, Dannhardt G, Ulbrich H, Hamburger M (2002) Inhibitory activity of tryptanthrin on prostaglandin and leukotriene synthesis. Planta Med 68:875-880
36. Berg J, Christoph T, Widerna M (1997) Isoenzyme-specific cyclooxygenase inhibitors: A whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. J Pharmacol Toxicol Methods 37:179-186
37. Kirkin V, Joos S, Zornig M (2004) The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644:229-249
38. Wang S, Yang D, Lippman ME (2003) Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 30(S16):133-142
39. Letai A (2006) Growth factor withdrawal and apoptosis: The middle game. Mol Cell 17:749-760
40. Yang-Yen HF (2006) Mcl-1: A highly regulated cell death and survival controller. J Biomed Sci 13:201-204
41. Tang R, Faussat AM, Majdak P (2006) Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 5:723-731
42. Rahmani M, Davis EM, Bauer C (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 280:35217-35227
43. Sharpe JC, Arnoult D, Youle RJ (2004) Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 1644:107-113
44. Denault JB, Salvesen GS (2002) Caspases: Keys in the ignition of cell death. Chem Rev 102:4489-4500
45. Philchenkov AA (2003) Caspases as regulators of apoptosis and other cell functions. Biochemistry 68:365-376
46. Smolewski P, Darzynkiewicz Z, Robak T (2003) Caspase-mediated cell death in hematological malignancies: Theoretical considerations, methods of assessment, and clinical implications. Leuk Lymphoma 44:1089-1104